The Long Island Brain Tumor Center at Neurological Surgery, P.C., is participating in the trials listed below.
To view additional information visit

For more information, please contact R. Kimberly Prabhu, MA, CCRP or Kerry McConie RN, OCN at (516) 478-0010

Newly Diagnosed Glioblastoma

  • Sponsor: Neurological Surgery, P.C. Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With
    Newly Diagnosed Glioblastoma (HBO)

Standard treatment for glioblastomas includes radiation and chemotherapy with a drug called temozolomide (Temodar); however, glioblastomas frequently develop resistance to standard treatment and recur or progress. Glioblastomas are known to have decreased levels of oxygen compared to normal tissues. There is evidence that these lower oxygen levels in glioblastomas may contribute to their ability to resist treatment effects of radiation and chemotherapy. In this study we will look to increase the oxygen concentration within the glioblastoma by adding hyperbaric treatments (the experimental part of this study) to standard treatment with radiation and temozolomide in order to see whether increasing the oxygen concentration within the tumor increases the tumor-killing ability of standard radiation and chemotherapy. 

  • Sponsor: Northwest Biotherapeutics
    A Phase III Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme

The purpose of the study is to determine the safety and efficacy of an investigational therapy called DCVax®-L in patients with newly diagnosed GBM for whom surgery is indicated. Patient must enter screening at a participating site prior to surgical resection of the tumor. Patients will receive standard of care, including radiation and Temodar therapy and two out of three will additionally receive DCVax®-L and the remaining one third will receive placebo. Patients randomized to placebo will have the option to receive DCVax®-L in a crossover arm upon documented disease progression. (note: DCVax®-L when used for patients with brain cancer is sometimes also referred to as DCVax-Brain)

Recurrent Glioblastoma

  • Sponsor: AbbVie, Inc.
    ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group

    This study is to evaluate the efficacy and safety of ABT-414 alone or with temozolomide versus temozolomide or lomustine alone in participants with recurrent glioblastoma multiforme.

  • Sponsor: Nativis, Inc.
    A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM)

    This feasibility study will assess the effects of the Nativis Voyager therapy in patients with recurrent GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to eleven subjects over six months. Safety and clinical utility will be evaluated.

  • Sponsor:  Cortice Biosciences, Inc.
    Phase II Dose-Escalation Study of TPI 287 in Combination with Bevacizumab in Adults with Recurrent Glioblastoma Safety and Efficacy Study of TPI 287 in Combination With Avastin (Bevacizumab) to Treat Glioblastoma

    The purpose of this study is to determine the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has recurred or progressed following prior radiation therapy and temozolomide (TMZ).

Expanded Access

  • Sponsor: Northwest Biotherapeutics
    An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients with Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221

The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process, but who subsequently failed to meet specific enrollment criteria. Patients will receive therapy per investigator discretion (standard of care) as well as active vaccine per the 020221 protocol administration schedule. It is estimated that approximately 99 patients will enroll in this study.     

  • Sponsor: Celldex Therapeutics CDX110-05

The study is an open-label expanded access study for patients who do not qualify for Celldex currently enrolling studies.




® All Rights Reserved 2014 | The Long Island Brain Tumor Center at Neurological Surgery P.C.




site by